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We conducted a multicenter, phase 1 dose escalation study evaluating the safety of the allogeneic multipotent
adult progenitor cell (MAPC, MultiStem, Athersys, Inc., Cleveland, OH) stromal product administered as an
adjunct therapy to 36 patients after myeloablative allogeneic hematopoietic cell transplantation (HCT). Patients
received increasing doses of MAPC (1, 5, or 10 million cells per kilogram recipient weight) as a single i.v. dose on
day þ2 after HCT (n¼ 18), or once weekly for up to 5 doses (1 or 5 million cells per kilogram; n¼ 18). Infusional
and regimen-related toxicities were assessed for 30 days after the last MAPC dose. Of 36 allogeneic HCT donors
(17 related and 19 unrelated), 35 were 6/6 HLA matched. MAPC infusions were well tolerated without asso-
ciated infusional toxicity, graft failure, or increased incidence of infection. Median times to neutrophil (n ¼ 36)
and platelet (n ¼ 31) engraftment were 15 (range, 11 to 25) and 16 (range, 11 to 41) days, respectively. The
overall cumulative incidences of grades II to IV and III and IV acute graft-versus-host disease (GVHD) at day 100
were 37% and 14%, respectively (n ¼ 36). In the group that received the highest single MAPC dose (10 million
cells/kg), day 100 incidence of grade II to IV GVHD was 11.1% (1 of 9) with no observed cases of grade III and IV
GVHD. We found no evidence for MHC class II allogeneic antibody induction, although some patients showed
an increase in serum anticlass I titers compared with baseline. MAPC contribution to blood chimerism was
negligible. These phase I data support the safety of stromal stem cell therapy and suggest that MAPC should be
tested prospectively as a novel therapeutic option for GVHD prophylaxis after HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Because of diverse and novel properties, stromal stem cell
therapies have been under active investigation as a novel
adjunct treatment in conjunction with hematopoietic celledgments on page 727.
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ty for Blood and Marrow Transplantation.transplantation (HCT). The biologic and immune-privileged
traits of mesenchymal stromal cells (MSC) fueled interest in
their clinical development as cellular therapeutics in the ﬁeld
of HCT [1,2]. Lazarus et al. were the ﬁrst to report the feasi-
bility and safety of using ex vivoeexpanded autologous and
donor allogeneic MSC for infusion into patients undergoing
myeloablative autologous and allogeneic HCT [1,3-5].
Although several groups originally reported a positive impact
of MSC infusion on engraftment after HCT [3,4,6], greater
focus has been for treatment of acute graft-versus-host
disease (GVHD), taking advantage of the MSC immunomod-
ulatory capacities. Le Blanc et al. [6] were the ﬁrst to report
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controlled life-threatening acute GVHD in the gastrointestinal
tract and liver. Since that time, subsequent reports have
demonstrated thatMSCwere successful in directing sustained
suppression of GVHD in additional patients experiencing se-
vere, steroid-refractory acute GVHD [7-9]; however, pre-
liminary reports of phase 3 trials of MSC for treatment of
newly diagnosed or steroid-refractory GVHD failed to achieve
sustained remission endpoints [10,11].
Multipotent adult progenitor cells (MAPC) are a class of
adult stem cells with commonality to MSC but with higher
proliferation capability and broader differentiation potential
[12]. MAPC are an adult adherent bone marrow (BM)e
derived progenitor cell population that meet criteria applied
toMSC, including expression of particular surface antigens as
well as the capacity to differentiate along mesenchymal
lineages. MAPC differ from MSC as they are isolated and
grown in hypoxic conditionswithmedia, supplementedwith
growth factors, and grown at some conﬂuent culture den-
sities. These conditions allow for maintaining activity of the
telomerase enzyme, which, as a consequence, contributes to
an increase in expansion capacity before senescence [13].
MAPC also possess active immunomodulatory and anti-
inﬂammatory properties [14-16], and comparison studies
with MSC in side-by-side cultures have been favorable [13].
The MultiStem (Athersys, Inc., Cleveland, OH) product is a
clinical-grade expanded MAPC population that appears
nonimmunogenic, can suppress activated T cell proliferation,
and has anti-inﬂammatory and angiogenic properties in both
in vitro and in vivo rodent models [15,17]. The isolation
conditions employed to produce the Multistem clinical
product allow expansion to 60 population doublings or
greater, compared with expansion limits of about 30 popu-
lation doublings under MSC conditions. The expansion
potential allows creation of a master cell bank as a
manufacturing intermediate with repeated production from
the master cell bank, such that all products used in the
described clinical study are derived from the same donor, are
expanded to the same population doublings, and also would
allow potential future phase 2 and phase 3 trials. GVHD
studies, arising from this ﬁrst study, would use product
derived from the same donor. Preclinical studies have shown
the safety of i.v. infusion of MAPC as well as a survival beneﬁt
in a haploidentical acute GVHD rodent model when admin-
istered in a prophylactic manner [18-20].
We designed a clinical study to address the safety and
efﬁcacy of MAPC product administration during the ﬁrst
month after allogeneic HCTdthe critical period for engraft-
ment and early onset of acute GVHDdin patients with he-
matologic malignancy. Additional preclinical studies were
undertaken to support the phase 1 observations and provide
insights on the dose and schedule of MAPC that could be
necessary for optimal clinical application. Herein, we present
these ﬁrst-in-human phase 1 and preclinical ﬁndings using
escalating single dose and multiple dose MAPC therapy after
allogeneic HCT.PATIENTS AND METHODS
This open-label, phase 1, multicenter, dose-escalation trial evaluating
single and repeated administration of allogeneic MAPC (MultiStem) was
undertaken in patients with acute myeloid (AML) or lymphoid leukemia
(ALL), chronic myeloid leukemia, or myelodysplasia. The study was
approved by the institutional review board at each center and each patient
provided written, informed consent after the study had been explained in
detail by the treating physician and staff.Study Population
Eligibility was speciﬁed for patients 18 through 65 years of age who were
eligible to undergo an allogeneic BM or mobilized peripheral blood HCT from
a matched related (MRD) or matched unrelated donor (MUD) at HLA-A, -B,
-DR (6/6 allelic match or 5/6 single allelic mismatch, with provision that the
DRB1 was molecularly matched). Diagnosis eligibility was speciﬁed for AML
or ALL in second or subsequent remission, induction failure with <20% BM
blasts, or ﬁrst remission AMLwith high cytogenetic risk (including del(5q)/-5,
del(7q)/-7, abn(3q), (9q), (11q), (20q), (21q), (17p), del(9q), t(6;9), t(9;22), and
complex karyotypes [3 or more]), or with identiﬁed mutations within the
FLT3 gene, or high-risk ALL in ﬁrst remission (including t(9;22)(q34;11),
t(4;11)(q21;q23), t(8;14)(q24.1;q32), low hypodiploidy or near triploidy,
complex karyotype with more than 4 abnormalities). Chronic myeloid leu-
kemia patients intolerant of tyrosine kinase inhibitor therapy or whose dis-
ease was resistant to therapy (accelerated phase, ﬁrst, or second chronic
phase), or myelodysplasia (intermediate/high or high risk by International
Prognostic Scoring System) of lower risk by International Prognostic Scoring
Systemwith patient having progressed after prior therapy also were deemed
eligible. Complete remission was deﬁned as adequate blood counts and the
absence of blasts in the peripheral circulation at the time of enrollment and
<5% blasts in the BM within 28 days of enrollment.
Four myeloablative conditioning regimens were allowed, based on the
patient’s disease and status, including: (1) cyclophosphamide (Cy) and total
body irradiation (TBI) with a TBI dose of at least 1200 cGy of fractionated
TBI; (2) etoposide and TBI, with a TBI dose of at least 1200 cGy of frac-
tionated TBI; (3) busulfan (Bu) and Cy, with at least 14 mg/kg Bu orally, 12.8
mg/kg intravenously, or targeted dose Bu; and (4) ﬂudarabine (Flu) and
melphalan (Mel) with a total dose of at least 120 mg/m2 of Flu administered
in divided doses in no less than 3 days and 100 mg/m2/day but no greater
than 140 mg/m2/day of Mel administered on transplantation day 1. GVHD
prophylaxis regimens permitted included methotrexate (MTX) at 15 mg/m2
i.v. on day þ1 and 10 mg/m2 i.v. on days þ3, þ6, and þ11 in combination
with either tacrolimus, administered i.v. or orally to maintain blood levels
between 5 and 15 ng/mL, or cyclosporine (CSA), administered to maintain
blood levels between 150 and 300 ng/mL. Patients were excluded from the
study if their calculated creatinine clearance <50 mL/minute, Karnofsky
score <60%, serology was positive for human immunodeﬁciency virus, they
had uncontrolled infections, or they had previously undergone hemato-
poietic cell or solid organ transplantation. For each patient, data were
collected through 100 days after transplantation to encompass endpoints of
this phase 1 study or until study withdrawal.Study Product
The MultiStem product is an expanded population of MAPC originating
from adherent adult stem cells harvested from the BM of an unrelated
volunteer, healthy donor [13,15,17,21]. For this study, stem cells isolated
from a single qualiﬁed donor were expanded ex vivo in cell factories to
create a cryopreserved master cell bank under current good manufacturing
practice. Subsequent expansions were used tomanufacture the current good
manufacturing practiceegrade MultiStem products. The clinical donor and
master cell bank were negative for presence of infectious agents, including
human immunodeﬁciency virus 1, human immunodeﬁciency virus 2, hep-
atitis B and C, West Nile virus, syphilis, Human T-Cell Lymphotropic Virus-1
and -2 (HTLV-1 and HTLV-2), cytomegalovirus (CMV), and Epstein-Barr vi-
rus. Transmissible spongiform encephalopathy and Creutzfeldt-Jakob dis-
ease risks were ruled out via health and questionnaire assessments. During
expansion for dose production from the master cell bank, in-process testing
was performed for bacterial and fungal contamination and for chromosomal
stability. The clinical MultiStem product is produced using fetal calf serum,
but before cryopreservation, the cells are washed in human serum albumin
so that if remnants of fetal bovine serum were present, they were below
detectable level. After expansion, the clinical cryopreserved products
contain DMSO, which after dilution before patient infusion has a concen-
tration of 5%.
Assigned cryopreserved batches were stored at each clinical site in
liquid nitrogen vapor phase until use for infusion. For infusion, clinical grade
MAPC product was thawed, diluted in an equal volume of Plasmalyte A
(Baxter, Deerﬁeld, IL) and sampled for measurement of the viable cell count
and retested for bacterial and fungal contamination. The dose of MAPC was
diluted based on the actual body weight of the recipient and, after recon-
stitution, cells were transferred into an infusion bag. The reconstituted
MAPC product was infused intravenously within 6 hours after thaw via the
patient’s central venous catheter at a rate of approximately 5 to 10 mL per
minute by gravity. Vital signs were recorded before dosing, every 15  5
minutes for 2 hours, and then every 41 hour for 48 hours from the start of
MAPC infusion during hospitalization. If dosing was performed on outpa-
tient basis, vital signs were collected before dosing and then every 15  5
minutes for 2 hours, then at 6 1 hours after infusion. Premedication before
Table 1
Patient Characteristics
Characteristics Single-Dose
Arm
Repeat-Dose
Arm
Overall
Age, median (range), yr 49.5 (31-61) 56 (20-62) 53.5 (20-62)
Sex
Male 10 10 20
Female 8 8 16
Disease
AML/ALL 10 15 25
CML 2 1 3
MDS 6 2 8
Donor
Related 7 10 17
Unrelated 11 8 19
Stem cell source
BM 2 0 2
PBSC 16 18 34
HLA matching
5/6 0 1 1
6/6 16 17 33
Conditioning
Cy-TBI 6 5 11
Bu-Cy 9 3 12
Flu-Mel 3 10 13
GVHD prophylaxis
MTX þ CSA 0 3 3
MTX þ FK-506 18 15 33
CML indicates chronic myeloid leukemia; MDS, myelodysplasia; PBSC, pe-
ripheral blood stem cells; FK-506, tacrolimus.
Data presented are (n) unless otherwise indicated.
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ticosteroids were excluded.
Endpoints
The primary endpoint for the study was safety of MAPC product admin-
istration assessed by evaluation of dose-limiting toxicities (DLTs) through 30
days afteradministrationof the lastMAPCdose. TheDLTdeﬁnition consistedof
the emergence of infusion-related allergic adverse events as well as regimen-
related toxicities (RRT). Speciﬁcally, aDLTwas triggeredbyoccurrence through
48 hours after MAPC infusion of grade 2 infusion-related allergic toxicities,
which include rash, ﬂushing, urticaria, dyspnea, fever  38C (100.4F) as
scored according to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0 [34]. In addition, a DLT was assigned if,
through 30 days after the last day of MAPC infusion, any grade 3 or 4 adverse
pulmonary, cardiac, renal, oral mucosal, or hepatic event or grade 4 adverse
events for other organs occurred per the Bearman scale [22]. Secondary end-
points were the incidence of acute GVHD, incidence of infection, and survival
throughday 100. Severity of infectionswas graded asmoderate, severe, or life-
threatening/fatal, according to the deﬁnitions in the Blood and Marrow
Transplant Clinical Trials Network (BMTCTN) TechnicalManual of Procedures,
Version 2, dated September 16, 2005 [35].
Kaplan-Meier estimates for GVHD were censored for death; relapse and
relapse-free survival rates were calculated using death and relapse as
events. All adverse events were documented through day 100. All analyses
were performed on an intent-to-treat basis.
Study Design
Patients were enrolled in 2 separate study arms of MAPC product
administration: they received either a single dose or multiple weekly doses.
In each arm, the total sample size was 18 patients, enrolled in 6 cohorts of 3
patients each. Day 0 was deﬁned as the day of HCT. In the single-dose arm, 3
predetermined MAPC doses were tested; namely, 1, 5, or 10 million cells per
kilogram of recipient weight, administered on day þ2 after HCT. In the
repeat-dose arm, the 3 predetermined dosing regimens included 1 or 5
million cells per kilogram, administered at days þ2, þ9, and þ16 after HCT
(1 or 5million cells per kilogram 3 weekly infusions), or 5 million cells per
kilogram, administered at days þ2, þ9, þ16, þ23, and þ30 after HCT (5
million cells per kilogram  5 weekly infusions).
Dose escalation was scheduled after each of 3 patients in a cohort had
completed the safety window 30 days after the last MAPC dose and DLTs
were assessed. The continual reassessment method (CRM) [23] was used to
determine the dosing regimen for the next cohort for dose escalation (see
statistical considerations). The ﬁrst cohort of patients on study was enrolled
in the single-dose arm to receive a single dose of 1 million MAPC cells/kg.
When the CRMmodel indicated escalation to the next single-dose level of 5
million cells/kg, the repeated-dose armwas activated for dosing at 1million/
kg  3 weekly doses and accrual occurred in parallel between the 2 arms.
Study Monitoring
Conduct of this trial was monitored by an independent safety commit-
tee, chaired by a medical safety monitor from the contract research orga-
nization responsible for trial conduct and 3 independent transplantation
physicians experienced in HCT trials whowere not enrolling patients for this
study. Safety data from all sites were transmitted to the medical safety
monitor in real-time for review of serious and severe events or deaths
judged to be related to MultiStem and for discussion with the safety com-
mittee, as needed. Safety committee meetings were held after completion of
each cohort to review safety data and conﬁrm safety of escalation to the next
dose level.
Statistical Considerations
The target toxicity probability was estimated at 25%, based on the ex-
pected level of RRT in HCT patients [23]. The CRMmethod employed a single
parameter Bayesian dose-response model in which the probability of
toxicity at each dose or dose-regimenwas modeled as pi exp(a) where pi is a
constant and the random variable a has a normal prior distribution with
mean 0 and variance 2. After each cohort of 3 subjects, the Bayesian prob-
abilities of toxicity were calculated for each predetermined dose group [23]
and the dose with the calculated toxicity probability closest to 25% was then
assigned to the next cohort. For each arm, a minimum of 18 patients was
needed to acquire statistical signiﬁcance. Consequently, the dose chosen by
the CRM after completion of the sixth cohort was then considered the
maximum-tolerated dose.
Correlative SciencedChimerism
A modiﬁed chimerism assay was implemented to evaluate the persistent
presence of MAPC in circulation and in tissue. For this assay determination,
peripheral blood samples were obtained before transplantation and on days4, 28  7, and 100  7 for analysis by polymerase chain reaction analysis. To
enable this assay, a blood sample from the transplant donor was also required
and separate consent from each transplant donor was acquired through the
National Marrow Donor Program (unrelated donors) or through the institu-
tional transplantation centers (related donors). Engraftment testing was
performed on a molecular level by detecting genetic differences between
recipients and HCT and MAPC donors using gene ampliﬁcation of highly
polymorphic repetitive loci variable number of tandem repeats (VNTRs) or
small tandem repeats (STRs). Ampliﬁcation results in speciﬁc products of
different sizes, which can distinguish recipient and donor alleles. Four VNTR
loci (D1S80, apoB, D1S111, and D17S5) and 5 STR loci (SE33, VWF STR1,
CSF1PO, TPOX, and THO1) were used. For the VNTR and STR loci, ﬂuorescently
labeled products were detected, analyzed, and quantiﬁed on a DNA
sequencer. Testingwas performed in 2 steps. First, pretransplantation analysis
determined which locus could be used to uniquely identify alleles for the
recipient, HCT donor, and MAPC donor. Second, post-transplantation analysis
determined the contributions of relative amounts of recipient DNA, HCT
donor DNA, and MAPC donor DNA. The sensitivity depended on the locus
used and the allele combinations present in the recipients and donors. Typical
sensitivity of the assay for detection of MAPC is 1% to 2% (ie, 1 or 2 MAPC can
be detected with conﬁdence in the background of 100 non-MAPC cells).
To monitor potential development of adaptive humoral immune re-
sponses against the allogeneic, single-donor MAPC product, blood samples
were obtained before transplantation and on days 4 and 100  7 for
detection of HLA antibodies by FACS-Pro analysis (Blood Center of Wis-
consin, Milwaukee, WI). In certain cases, subsequent identiﬁcation analysis
was performed to assess whether antibodies were directed against speciﬁc
HLA haplotype epitopes present on the MAPC product. For this purpose, the
high-resolution haplotype of the single MAPC donor was established and
used to identify relevant target HLA protein antigens on the product.RESULTS
Patient and Transplantation Characteristics
Between October 2008 and September 2011, 36 patients
were enrolled in the study at 5 institutions in the United
States and 1 in Belgium, with 18 patients accrued in each of
the MAPC single-dose and repeat-dose administration
groups. The demographics and transplantation characteris-
tics of the study population are summarized in Table 1.
Overall, 34 patients received peripheral blood cell trans-
plants, and 2 subjects received BM allografts. The majority of
Table 2
Summary of Product Administration, Exposure and Compliance for Each
Dose Group
Dose Group Patient
(n)
Total Volume
Infused, mL
Total Product
Exposure,
Millions of
Cells
Planned
Product
Received, %
Single-dose arm
1 million/kg  1 6 23-61 90-133 112-125
5 million/kg  1 3 100-143 314-600 116-126
10 million/kg  1 9 133-294 560-1245 94-108
Repeat-dose arm
1 million/kg  3 3 62-83 253-322 103-123
5 million/kg  3 3 232-295 1100-1394 97-103
5 million/kg  5 12 239-534 1104-2690 39*-127
* Three patients received only the ﬁrst 2, 3, or 4 of the scheduled 5 doses,
respectively.
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prophylaxis and 2 patients received MTX and CSA. Eleven
patients received Cy-TBI, 12 patients received busulfan-Cy,
and 13 patients received Flu-Mel conditioning regimens.
Thirty-ﬁve (97%) patients had 6/6 HLA-A, -B, and -DR
matched and 1 patient received a 5/6 HLA-matched stem cell
product, mismatched at the HLA-A locus; of the donors, 17
subjects received transplants from MRD, 18 from MUD, and
the single A mismatch within the unrelated cohort.
Between the single-dose and repeat-dose arms, there
were imbalances in conditioning, GVHD prophylaxis regi-
mens, and transplantation source (Table 1). The 2 subjects
who received BM grafts were randomly assigned to the 1 and
10 million cells per kilogram single MAPC dose groups. All 3
patients who received MTX and CSA were assigned to the 5
million cells per kilogram  5 weekly MAPC dose group. The
majority of patients (10 of 13) receiving the Flu-Mel condi-
tioning regimen were assigned to the repeat-dose arm.Clinical Safety Outcomes
DLT assessment
The study was designed to evaluate the safety of either a
single dose or multiple doses of MAPC product in patients
after HCT. A total of 90 MAPC infusion procedures were
performed in 36 patients with no observed infusion-related
toxicity. Three patients experienced a potential DLT event,
triggered by an RRT within 30 days of MAPC administration.Table 3
Summary of Number of Patients with Adverse Events and Severe Adverse Events
Variable MAPC Dose Groups
Single Dose, million cells/kg Repeat
1 (n ¼ 6) 5 (n ¼ 3) 10 (n ¼ 9) 1  3 w
1 Adverse event 6 3 9 3
1 Severe adverse event 2 2 5 1
Highest NCI grade or severity
Grade 1 0 0 0 0
Grade 2 0 0 1 0
Grade 3 0 0 2 2
Grade 4 6 2 5 1
Grade 5 0 1 1 0
Relationship*
Not related 6 3 8 3
Related 0 0 1 0
NCI indicates National Cancer Institute.
Data represent number of patients. At each level of summation (except for the row
counted only once.
* Not related indicates unrelated or unlikely relationship; related indicates a p
deﬁnitely related.These included grade 3 mucositis (1 million/kg single-dose
group), grade 3 hypoxic respiratory failure and grade 3
renal failure (10 million/kg single-dose group), and grade 4
hyperbilirubinemia. Overall, the various tested MAPC dosing
paradigms were well tolerated. The highest administered
single dose of 10 million cells per kilogram and the highest
repeat-dose regimen of 5 million cells per kilogram given 5
times weekly were declared the maximum tolerated doses
via the CRM procedure, as per protocol. There were no DLT in
these highest-tested cohorts. There was no provision in the
trial design for further dose escalation beyond the preas-
signed dose levels.
With respect to compliance of product administration, all
18 patients in the single-dose arm and 15 of 18 patients in the
repeat-dose arm received all scheduled MAPC doses
(Table 2). As required per protocol, 2 patients in the 5-weekly
dose cohorts only received the ﬁrst 3 and 4 of the assigned 5
doses because of onset of severe acute or steroid refractory
GVHD before completing the dosing schedule. One patient in
the 5-weekly dose group declined additional MAPC after the
ﬁrst 2 infusions. The maximum MAPC cell exposure in indi-
vidual recipients in the study was 1.25 billion cells single
dose and 2.69 billion cells, cumulatively, in the 5-weekly
repeated-dose arm (Table 2). The approximate ranges of
infusion volumes for the 3 tested dose levels per infusion
were 23 to 61 mL for 1 million/kg, 100 to 143 mL for 5
million/kg, and 133 to 294 mL for the 10 million/kg single-
dose level. Twenty patients received premedication with
acetaminophen and/or diphenhydramine before product
infusion at the investigator’s discretion. Of the 16 patients
who were not premedicated, 4 received the highest dose of
10millionMultiStem per kilogram and 9 patients received all
5 doses at 5 million cells per kg.
Adverse events
Adverse and serious adverse events were evaluated
through 100 days after transplantation. All 36 HCT patients
experienced at least 1 adverse event during the 100-day eval-
uation period (Table 3), in general agreement with the expec-
tation for this patient population [4]. In 18 of 36 (50%) patients,
a grade 4 adverse event was observed. Only 5 patients man-
ifestedadverseevents thatweredeemed(possiblyorprobably)
treatment related. In the single-dose arm, 2 events were
considered possibly related to treatment (increased hepaticTotal (n ¼ 36)
Dose, million cells/kg  wk
k (n ¼ 3) 5  3 wk (n ¼ 3) 5  5 wk (n ¼ 12)
3 12 36
3 10 23
0 0 0
0 1 2
1 7 12
1 3 18
1 1 4
3 8 31
0 4 5
for 1 severe adverse event), patients reporting more than 1 event were
ossible, probable, or deﬁnite relationship. No adverse events were deemed
Table 4
Summary of Number and Severity of Infections and Types of Pathogens
MAPC Dose Groups Total (n ¼ 36)
Single Dose, million cells/kg Repeat Dose, million cells/kg  wk
1 (n ¼ 6) 5 (n ¼ 3) 10 (n ¼ 9) 1  3 wk (n ¼ 3) 5  3 wk (n ¼ 3) 5  5 wk (n ¼ 12)
No. of subjects who experienced
any infection
3 2 5 3 2 9 24
Total no. of infections 10 5 15 8 6 18 62
No. of severe/fatal infections* 4 4y 6 1 2 5 22y
Bacterial (severe) 3 2 (1) 7 (3) 5 (1) 6 (2) 7 (2) 30 (9)
Viral (severe) 7 (4) 3 (3y) 6 (2) 3 0 9 (3) 28 (12y)
Fungal (severe) 0 0 2 (1) 0 0 0 2 (1)
Other 0 0 0 0 0 2z 2
CMV reactivation 1 0 2 1 0 3 7
* Severity graded according to the deﬁnitions in the BMT-CTN (https://web.emmes.com/study/bmt2/public/MOP/BMT_CTN_Technical_MOP_ver_2.0.pdf).
y Includes 1 fatal infection.
z 1 case of protozoan infection (sporozoa) and 1 case of pneumonia with unknown etiology.
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alanine aminotransferase). In the repeated-dose arm, 3 events
were considered possibly related to treatment (abnormal liver
function tests, hyperbilirubinemia, and relapse of underlying
AML). In addition, in 1 case, nausea and vomiting, observed in
the repeat-dose arm within 48 hours of the ﬁrst dose, was
assigned as probably related to treatment. Administration of
the remaining 4 doses occurred without incident. In no cases
were adverse events attributed as deﬁnitely related to
administered product.
Infections
In the study, 24 patients experienced a total of 62 in-
fections up to day 100, consisting of 30 bacterial, 28 viral, 2
fungal, and 2 classiﬁed as “others” (Table 4). Thirty infections
were observed in the single-dose arm (12 bacterial, 16 viral,
and 2 fungal) and 32 occurred in the repeat-dose arm (18
bacterial, 12 viral, and 2 deﬁned as “other,” including 1 case
of protozoan infection [sporozoa] and 1 lung infection with
unknown etiology). Seven of the 28 viral infections were
CMV-reactivation events; 3 in the single-dose and 4 in the
repeat-dose arm (Table 4). Overall, 12 of 36 patients (33%)
had no infections, 10 patients (28%) had 1 infection, and the
remaining 39% had 2 or more infections during the 100-day
observation period.
Using the deﬁnitions from the BMT CTN [35], of all 62
events, 40 were graded as moderate and 22 as severe in-
fections (including 1 fatal event from disseminated adeno-
virus). Overall, 9 of 30 bacterial infections were graded
severe (4 of 12 in single-dose arm, 5 of 18 in repeat-dose
arm). Twelve of 28 viral infections were graded severe
(with the single fatal event due to disseminated adenovirus
infection), of which 9 of 16 and 3 of 12 were observed in the
single-dose and repeat-dose arms, respectively. One of the 2
fungal infections in the single-dose arm was graded severe.
Clinical Response
Engraftment
Myeloid engraftment occurred in all 36 patients. Platelet
engraftment was observed for 31 of 36 patients, with 5 pa-
tients requiring ongoing platelet transfusions through day
100; 4 in the single-dose arm and 1 in the repeat-dose arm.
Themedian times to neutrophil (n¼ 36) and platelet (n¼ 31)
engraftment were 15 (range, 11 to 25) and 16 (11 to 41) days,
respectively, and were not different between the single or
multiple-dose cohorts.Relapse and survival
Within the 100-day evaluation period, 3 patients experi-
enced relapse of the underlying disease. Two of these pa-
tients were in the single-dose arm and 1 patient had been
assigned to the repeat-dose arm. These patients were sub-
sequently withdrawn from the study at that time (as
immunosuppressive therapy was withdrawn in these pa-
tients in an attempt to increase graft-versus-leukemia ac-
tivity, placing them at high risk for induced acute GVHD).
Four patients died on study during the 100-day evaluation
period; 1 each as a result of disseminated adenovirus-
associated liver failure, respiratory failure, acute GVHD of
the gastrointestinal tract, and acute GVHD of the liver. The
probability of day 100 overall survival for all patients was
91.1% (95% conﬁdence interval, 75% to 97%). The probability
of day 100 disease-free survival for all patients was 81% (95%
conﬁdence interval, 63% to 90%). Overall relapse rates were 3
of 36 patients or 8%, with overall mortality at 4 of 36, or 11%,
within the study period.
Acute GVHD
The cumulative incidences of grade II to IV and grade III
and IV GVHD for all 36 patients are shown in Figure 1A and
the frequencies of GVHD in each dose group are shown in
Table 5. The day 100 Kaplan-Meier estimates for grade II to IV
and grade III and IV GVHDwere 37% and 14%, respectively, for
all 36 patients on study. Through day 100, the overall inci-
dence of steroid-refractory GVHD in the trial was 5.6% (2 of
36 patients). For the single-dose arm, day 100 incidences for
grades II to IV and III and IV GVHD were 28% and 6%,
respectively. In 9 patients who received 10 million MAPC per
kilogram single dose, the day 100 incidences were 11.1% and
0% for grades II to IV and III and IV GVHD, respectively
(Figure 1B,D). In the repeat-dose arm, day 100 incidences for
grades II to IV and III and IV GVHD were 45% and 19%,
respectively. There were no differences in GVHD frequency
between the repeat-dose groups (Table 5), although it was
noted that several of the observed events occurred after day
60 (Figure 1 C,D). Within the high repeat-dose group, 3 pa-
tients were treated with MTX and CSA as GVHD prophylaxis
with its recognized higher anticipated GVHD incidence [24],
1 patient received a single antigen mismatched product, 3
underwent total body radiationebased conditioning, and 4
of the 12 patients with the 5 treatment dose cohort received
unrelated donor products, possibly contributing factors to
the lack of perceived GVHD response. Based on the excellent
Figure 1. Cumulative incidences of acute GVHD after MAPC product therapy observed in study patients. Grades II to IV (solid line) and III and IV GVHD (broken line)
are shown for all patients on study (A). Grade II to IV GVHD (B,C) and grade III and IV GVHD incidences (D,E) are presented for all dose, single, and repeat-dose groups,
respectively.
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IV GVHD of 11.1% and no cases of grade III and IV GVHD by
day 100, the 10 million cells/kg single-dose cohort was
identiﬁed as the cohort of interest.
Correlative StudiesdChimerism and Immunology
A MAPC-speciﬁc chimerism assay, developed to evaluate
presence of MAPC in the circulation and in tissues after
infusion, detected no MAPC donor-derived signal (VNTRs/
STRs) in circulating blood samples obtained on trans-
plantation days 4, 30, or 100 (n ¼ 36). MAPC chimerismTable 5
Summary of GVHD Incidence through Day 100 for Each Dose Group
MAPC Dose Groups
Single Dose, million cells/kg
1 (n ¼ 6) 5 (n ¼ 3) 10 (n ¼ 9)
Grade II-IV GVHD 2 (33%) 2 (67%) 1 (11%)
Grade III-IV GVHD 0 (0%) 1 (33%) 0 (0%)
SR-GVHD 0 (0%) 0 (0%) 0 (0%)
SR-GVHD indicates steroid refractory graft-versus-host disease.
Data presented are n (%).analysis was also performed on a limited number of skin (n¼
4) and gastrointestinal (n ¼ 4) biopsies obtained from 8
different study patients during diagnostic workup of ﬁrst
presentation of GVHD, without detection of the presence of
MAPC at the 1% to 2% level of sensitivity (data not shown).
Assays for serologic immunogenicity of theMAPC product
were performed. In 18 of 36 subjects, serumwas negative for
the presence of HLA antibody at any time (9 subjects in the
single-dose arm and 9 subjects in the repeat-dose arm). In 10
of 36 subjects, pre-existing HLA antibody was detected at
baseline and there was either no change afterRepeat Dose, million cells/kg  wk
1  3 wk (n ¼ 3) 5  3 wk (n ¼ 3) 5  5 wk (n ¼ 12)
1 (33%) 2 (67%) 5 (42%)
0 (0%) 1 (33%) 3 (25%)
0 (0%) 1 (33%) 1 (8%)
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body (5 subjects in the single-dose arm and 5 subjects in the
repeat-dose arm). Eight of 36 subjects were either negative
for HLA antibody at baseline and positive after trans-
plantation or showed an increase in HLA antibody titer from
baseline, mainly in HLA class I reactive antibody (4 subjects
in the single-dose arm and 4 subjects in the repeat-dose
arm). In this group, a single subject in the repeat-dose arm
showed, at day 100, the presence of HLA antibody against
class I epitope B35, which is present on the MAPC product
(data not shown). Another subject in the single-dose arm
showed initial reactivity against MAPC HLA class I epitope
A34 on day 4, but this was not observed again in the follow-
up analysis (data not shown). Overall, no convincing evi-
dence of anticlass I reactivity was seen and there was a
complete absence of HLA antibody development against
known class II antigens on the MAPC product.
DISCUSSION
We report the ﬁrst-in-human allogeneic HCT study of the
MultiStem MAPC product, an immunomodulatory, BM-
derived, adult adherent allogeneic stromal cell product that
can be manufactured to clinical scale [13,20,21]. Our data
demonstrate the feasibility and safety of a uniform cell
product derived from a single qualiﬁed MAPC donor for in-
fusions administered during the early post-HCT period,
beginning 2 days after transplantation and then escalated to
weekly interval treatments for 2 or 4 additional doses. The
speciﬁc timing of the initial MAPC dosewas selected so as not
to coincide with dosing of MTX, which is routinely admin-
istered 1, 3, 6, and 11 days after transplantation. Further, the
3- and 5-weekly dosing regimens were chosen to take into
consideration the pre-engraftment and early postengraft-
ment periods, during which patients in phase III studies
commonly demonstrate emergence of acute GVHD at me-
dian day 22 to 24 [25-29].
MAPC infusions were well tolerated as there was no
observed infusional toxicity after single or repeat adminis-
tration in any of the 36 patients enrolled in the study. Pre-
medication for product administration was left to the
discretion of the treating physician. Early in the study, 20
subjects received premedication only with diphenhydramine
and/or acetaminophen, whereas 16 patients subsequently
received no premedications. No difference in tolerance of the
infusions could be detected between these cohorts. Further,
we observed no speciﬁc or serious adverse events deemed
deﬁnitively related to study treatment through 100 days af-
ter transplantation (Table 3).
Hematopoietic engraftment was robust and consistent
with expectations for this patient population undergoing HCT,
similar to outcomes of patients treated on recent BMT CTN
clinical trials [26,27]. No patients experienced primary or
secondary engraftment failure. The incidence or patterns of
infections observed were comparable to data from the Center
for International Blood and Marrow Transplant Research as a
historic control database. For example, in a recent study of
patients undergoing unrelated transplantation, by 100 days,
between 68% and 86% of patients experienced bacterial in-
fections and 45% of patients experienced viral infections by 6
months, the highest percentage related to CMV reactivation.
Other current Center for International Blood and Marrow
Transplant Research studies are investigating incidence of
bacterial and viral infections in the immediate neutropenic
and postengraftment periods. Certainly, infections during the
neutropenic period after a myeloablative allogeneictransplantation procedure are anticipated; however, 1 prior
study demonstrated that approximately 50% of late infections
occur between day 50 and day 100 after transplantation [30].
Even reduced-intensity transplantation, with its low associ-
ated neutropenic days, had up to a 27% incidence of bacterial
infections within the ﬁrst 100 days [31]. In our study, a total of
62 infections occurred, 22 of which were severe, in the course
of patients with hematologic malignancy receiving myeloa-
blative conditioning. Further, of the 36 subjects on study, 12
patients (33%) were completely free of any invasive infection
through day 100 after transplantation, whereas 10 patients
(28%) experienced a single infectious event during this period
(Table 4). Only a single, fatal infection from disseminated
adenovirus was observed in the 5  106/kg single MAPC dose
arm. In all, this study established that the highest tested
single-dose and repeat-dose regimens after HCT were safe
and well tolerated.
Regimens for GVHD prophylaxis after allogeneic HCT reg-
imens have shown limited evolution over the last 15 years and
innovations in this area are needed to further reduce the
incidence of acute GVHD without increasing relapse or in-
fectious risks [25]. Recent data from phase 3 BMT CTN studies
of acute GVHD provide a modern baseline of approximately
34% and 46% grade II to IV acute GVHD, for MRD and MUD,
respectively [25,26]. For these reasons, stromal stem cell
therapy is under active investigation as a novel adjunct
treatment after HCT. No control arms were included in this
open-label phase 1 safety trial, but the day 100 incidence of
acute GVHD after MAPC therapy (Table 5) for all patients was
favorable compared with the historical rates in similar patient
populations, (eg, 47% to 74% grade II to IV GVHD after MUD
and 32% to 44% after MRD, respectively) [26,27].
We hypothesized that repeated doses of MAPC adminis-
tered in the ﬁrst 4 weeks after allogeneic HCT might provide
additional prevention against emergence of acute GVHD,
based on the temporal requirements for logarithmic clonal
expansion of allo-reactive T cells. Although the repeated-
dose groups studied did not appear to have this effect,
emergence of acute GVHD was delayed beyond the typical
window of 60 days after HCT in some of the cases
(Figure 1C,E, Table 5) and it is possible that during the trial
accrual process, patients with higher risk for development of
acute GVHD were randomly assigned to this cohort. The
study population of 36 patients was too small to determine
dose response, but it was observed that the rates of grade II
to IV acute GVHD appeared to be lower with higher dose
MAPC exposure, with lowest levels associated with the
highest dose (10 million cells/kg) administered at day 2 after
HCT. The cohort of 9 patients who received the 10 million
cells/kg single dose may be of greatest interest. Within that
group, all patients received MTX and tacrolimus GVHD pro-
phylaxis, 5 of 9 patients received unrelated products (4 pe-
ripheral blood stem cells; 1 BM), and 1 patient underwent a
single antigenemismatched transplantation procedure.
Here, the day 100 incidence of grade II to IV GVHD was 11.1%
and there were no cases of grade III and IV GVHD or steroid-
refractory GVHD (Figure 1, Table 5). For logistic reasons,
however, the 10 million cells/kg single dose was not tested in
the repeat-dose arm. Taken together with the safety proﬁle
described above, these data suggest that a single high dose of
MAPC given 2 days after HCT may have the potential to
provide effective prophylaxis for clinically signiﬁcant acute
GVHD and warrants further study. This observation is remi-
niscent of the emerging data supporting early utilization of
post-transplantation Cy, a potent immunosuppressive agent
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tered on days 3 and 4 after transplantation [32,33]. We
theorize that MAPC infusion similarly may limit homeostatic
T cell expansion and enhance engraftment of memory cells in
depleted lymphoid tissue. Our previously reported correla-
tive preclinical animal studies also supported these obser-
vations [18].
Our correlative studies to assess MAPC biodistribution
and immune responses against the allogeneic MAPC prod-
uct demonstrated no detection of a MAPC donor-derived
signal in the circulation or in a select set of tissue sam-
ples. Initial chimerism studies were performed using VNTR-
based polymorphism assay with sensitivities on the order of
detection of 1% against patient cell sampling. Although
quantitative polymerase chain reaction (qPCR) or deep
sequencing approaches targeting unique loci in the hyper-
variable HLA regions have been proposed for higher sensi-
tivity detection, their use for speciﬁc detection of MAPC
remains to be developed and validated. In addition, a ﬂow
cytometric assay was used to measure HLA antibodies in
MAPC recipients. Overall, there was no indication of sig-
niﬁcant development of HLA antibodies against the allo-
geneic MAPC product after single or repeat-dose
administration.
In summary, our phase 1, multi-institutional clinical trial
demonstrated that administration of MAPC in the immediate
post-HCT period for patients undergoing myeloablative
allogeneic HCT is feasible, safe, and well tolerated. Acute
GVHD rates were not increased and 1 of the dosing schedules
has been identiﬁed as most promising. Collectively, these
data, in conjunction with in vivo and in vitro preclinical ob-
servations, support further investigation on how to maxi-
mize clinical efﬁcacy of administering MAPC in acute GVHD
prophylaxis settings and a follow-up phase 2/3 trial is under
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